EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitomycin-C Use and Complications in Ophthalmology

Tongabay Cumurcu

International Journal of Clinical and Experimental Ophthalmology · 2017

DOI: 10.29328/journal.hceo.1001004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical and Experimental Ophthalmology, 2017. Verfasst von Tongabay Cumurcu. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitomycin-C, irst found its way into ophthalmic use in 1969, in Japan, where recurrent pterygia were successfully treated with the drug which is an antineoplastic / antibiotic agent isolated from the soil bacterium Streptomyces caespitosus [1]. It is an anti-metabolite with anti-proliferative effect on cells showing the highest rate of mitosis by inhibiting DNA synthesis and interferes with RNA transcription and protein synthesis [2].

Zitieren

APA

Cumurcu, T. (2017). Mitomycin-C Use and Complications in Ophthalmology. International Journal of Clinical and Experimental Ophthalmology. https://doi.org/10.29328/journal.hceo.1001004

Vancouver

Cumurcu T. Mitomycin-C Use and Complications in Ophthalmology. International Journal of Clinical and Experimental Ophthalmology. 2017. doi:10.29328/journal.hceo.1001004

BibTeX
@article{Cumurcu2017,
  author = {Cumurcu, Tongabay},
  title = {Mitomycin-C Use and Complications in Ophthalmology},
  journal = {International Journal of Clinical and Experimental Ophthalmology},
  year = {2017},
  doi = {10.29328/journal.hceo.1001004}
}
Kostenlos starten →